Candace H. Duncan
Known title: DirectorCIK: 0001606555
Associated companies
Transaction History
| TFX | ▲ Buy | Grant | 1,090 | $0 | 5/15/2026 | View on chart |
| TFX | ▲ Buy | Grant | 1,051 | $0 | 5/9/2025 | View on chart |
| TFX | ▲ Buy | Option Exercise | 4,833 | $595K | 5/5/2025 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 4,705 | $595K | 5/5/2025 | View on chart |
| TFX | ▲ Buy | Grant | 649 | $0 | 5/7/2024 | View on chart |
| TFX | ▲ Buy | Grant | 527 | $0 | 5/9/2023 | View on chart |
| TFX | ▲ Buy | Grant | 399 | $0 | 5/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate
Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate. Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.